AbbVie Gets EC Approval of Rinvoq for Adults With Rheumatoid Arthritis

By Colin Kellaher

AbbVie Inc. (ABBV) on Wednesday said the European Commission approved Rinvoq for the treatment of adults with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs.

The North Chicago, Ill., biopharmaceutical company said Rinvoq may be used as monotherapy or in combination with methotrexate.

AbbVie said the EC approval was supported by data from a global phase 3 program in which Rinvoq met all primary and ranked secondary endpoints across a variety of adult populations.

The U.S. Food and Drug Administration earlier this year approved the drug for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 18, 2019 11:22 ET (16:22 GMT)

AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024